218 related articles for article (PubMed ID: 20508609)
1. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.
Jäger R; Gisslinger H; Passamonti F; Rumi E; Berg T; Gisslinger B; Pietra D; Harutyunyan A; Klampfl T; Olcaydu D; Cazzola M; Kralovics R
Leukemia; 2010 Jul; 24(7):1290-8. PubMed ID: 20508609
[TBL] [Abstract][Full Text] [Related]
2. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
3. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
[TBL] [Abstract][Full Text] [Related]
4. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
6. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan.
Yang YL; Hung CC; Chen JS; Lin KH; Jou ST; Hsiao CC; Sheen JM; Cheng CN; Wu KH; Lin SR; Yu SL; Chen HY; Lu MY; Wang SC; Chang HH; Lin SW; Su YN; Lin DT
Cancer Sci; 2011 Oct; 102(10):1874-81. PubMed ID: 21740479
[TBL] [Abstract][Full Text] [Related]
7. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.
Klampfl T; Harutyunyan A; Berg T; Gisslinger B; Schalling M; Bagienski K; Olcaydu D; Passamonti F; Rumi E; Pietra D; Jäger R; Pieri L; Guglielmelli P; Iacobucci I; Martinelli G; Cazzola M; Vannucchi AM; Gisslinger H; Kralovics R
Blood; 2011 Jul; 118(1):167-76. PubMed ID: 21531982
[TBL] [Abstract][Full Text] [Related]
8. Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.
de Rooij JD; Beuling E; van den Heuvel-Eibrink MM; Obulkasim A; Baruchel A; Trka J; Reinhardt D; Sonneveld E; Gibson BE; Pieters R; Zimmermann M; Zwaan CM; Fornerod M
Haematologica; 2015 Sep; 100(9):1151-9. PubMed ID: 26069293
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
10. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
11. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
12. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
[TBL] [Abstract][Full Text] [Related]
13. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
[TBL] [Abstract][Full Text] [Related]
14. Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.
Tao J; Zhang X; Lancet J; Bennett JM; Cai L; Papenhausen P; Moscinski L; Zhang L
Cancer Genet; 2014; 207(10-12):489-94. PubMed ID: 25453399
[TBL] [Abstract][Full Text] [Related]
15. COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia.
Lopes BA; Meyer C; Barbosa TC; Zur Stadt U; Horstmann M; Venn NC; Heatley S; White DL; Sutton R; Pombo-de-Oliveira MS; Marschalek R; Emerenciano M
Oncotarget; 2016 Aug; 7(33):53064-53073. PubMed ID: 27419633
[TBL] [Abstract][Full Text] [Related]
16. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
[TBL] [Abstract][Full Text] [Related]
17. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
[TBL] [Abstract][Full Text] [Related]
18. IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
Gupta SK; Bakhshi S; Kumar L; Seth R; Kumar R
Leuk Res; 2016 Feb; 41():7-11. PubMed ID: 26704074
[TBL] [Abstract][Full Text] [Related]
19. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
[TBL] [Abstract][Full Text] [Related]
20. How new advances in genetic analysis are influencing the understanding and treatment of childhood acute leukemia.
Roberts KG; Mullighan CG
Curr Opin Pediatr; 2011 Feb; 23(1):34-40. PubMed ID: 21169835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]